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 2 
ABSTRACT 26 
Wallerian degeneration of physically injured axons involves a well-defined molecular 27 
pathway linking loss of axonal survival factor NMNAT2 to activation of pro-28 
degenerative protein SARM1. Manipulating the pathway through these proteins led 29 
to the identification of non-axotomy insults causing axon degeneration by a 30 
Wallerian-like mechanism, including several involving mitochondrial impairment. 31 
Mitochondrial dysfunction is heavily implicated in Parkinson’s disease, Charcot-32 
Marie-Tooth disease, hereditary spastic paraplegia and other axonal disorders. 33 
However, whether and how mitochondrial impairment activates Wallerian 34 
degeneration has remained unclear. Here, we show that disruption of mitochondrial 35 
membrane potential leads to axonal NMNAT2 depletion in mouse sympathetic 36 
neurons, increasing the substrate-to-product ratio (NMN/NAD) of this NAD-37 
synthesising enzyme, a metabolic fingerprint of Wallerian degeneration. The 38 
mechanism appears to involve both impaired NMNAT2 synthesis and reduced 39 
axonal transport. Expression of WLDS and Sarm1 deletion both protect axons after 40 
mitochondrial uncoupling. Blocking the pathway also confers neuroprotection and 41 
increases the lifespan of flies with Pink1 loss-of-function mutation, which causes 42 
severe mitochondrial defects. These data indicate that mitochondrial impairment 43 
replicates all the major steps of Wallerian degeneration, placing it upstream of 44 
NMNAT2 loss, with the potential to contribute to axon pathology in mitochondrial 45 
disorders.  46 
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INTRODUCTION 50 
Studies of axon degeneration following axotomy (Wallerian degeneration) and of the 51 
axon-protective protein WLDS have led to the discovery of critical endogenous 52 
regulators of the mechanisms resulting in axon degeneration (Conforti et al., 2014; 53 
Gerdts et al., 2016). The current model predicts that the pathway regulating 54 
Wallerian degeneration (Wallerian pathway) is activated by the loss in the axon of 55 
the labile nicotinamide mononucleotide adenylyl-transferase 2 (NMNAT2), a 56 
nicotinamide adenine dinucleotide (NAD)-synthesising enzyme. Axonal NMNAT2 57 
levels decline within a few hours when its transport and/or synthesis are impaired 58 
(Gilley and Coleman, 2010). Downstream of NMNAT2 depletion, the pro-59 
degenerative protein sterile alpha and TIR motif-containing protein 1 (SARM1) 60 
executes the degeneration program (Gerdts et al., 2015; Gilley et al., 2015; Loreto et 61 
al., 2015; Osterloh et al., 2012). To date, expression of WLDS/NMNATs (which 62 
substitute for endogenous NMNAT2 loss) and SARM1 depletion are the most 63 
effective means to block the Wallerian pathway and preserve axons in mammals. 64 
There is still debate about how NMNAT2 loss leads to SARM1 activation but the rise 65 
in its substrate, NMN, appears to be important (Cohen, 2017; Di Stefano et al., 2015, 66 
2017; Loreto et al., 2015; Zhao et al., 2019) as well as the fall in its product, NAD 67 
(Essuman et al., 2017; Gerdts et al., 2015; Sasaki et al., 2016). 68 
Most studies on the Wallerian pathway have used a physical injury model, but there 69 
is clear evidence that related degenerative mechanisms can be activated by many 70 
non-injury stresses (Conforti et al., 2014). However, the vast majority of non-axotomy 71 
models were performed when a more comprehensive understanding of the Wallerian 72 
pathway was lacking and were mostly identified as being Wallerian-like by targeting 73 
just a single step in the pathway (either by expressing of WLDS/NMNATs or, more 74 
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recently, by Sarm1 deletion). Both WLDs and SARM1 have the potential to influence 75 
other cellular mechanisms, such as nuclear NAD synthesis and innate immunity, 76 
respectively, so involvement of the Wallerian pathway is best supported by multiple 77 
lines of evidence.  78 
The link between mitochondria and the Wallerian pathway is particularly intriguing. 79 
Mitochondrial dysfunction is a common theme in a wide group of neurodegenerative 80 
disorders in which axon degeneration is central, including Parkinson’s disease (PD), 81 
Charcot-Marie-Tooth disease, hereditary spastic paraplegia and Friedrich’s ataxia 82 
(Court and Coleman, 2012). We and others have previously shown that mitochondria 83 
contribute to the later stages of Wallerian degeneration, where the axotomy itself 84 
activates the Wallerian pathway (Barrientos et al., 2011; Loreto et al., 2015). 85 
However, mitochondrial depolarisation, caused by the mitochondrial 86 
uncoupler Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), also leads to 87 
degeneration of uninjured axons (Loreto et al., 2015), which is rescued by Sarm1 88 
deletion (Summers et al., 2014). Additional studies, both in vitro and in vivo, link the 89 
Wallerian pathway to mitochondrial impairment. WldS mice are protected against 90 
nigrostriatal axon degeneration after intraperitoneal administration of the 91 
mitochondrial complex-1 inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 92 
(MPTP) (Hasbani and O’Malley, 2006). WLDS also preserves neurites and promotes 93 
neuronal survival in primary dopaminergic neurons treated with MPP+ (the active 94 
metabolite of MPTP) (Antenor-Dorsey and O’Malley, 2012). Finally, NMNATs 95 
overexpression and Sarm1 deletion in sensory neurons delay axon degeneration 96 
caused by rotenone, another mitochondrial complex-1 inhibitor, in sensory neurons 97 
(Press and Milbrandt, 2008; Summers et al., 2014). Thus, we hypothesised that 98 
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mitochondrial impairment can also act as an upstream cause, equivalent to physical 99 
injury, in initiating the Wallerian pathway. 100 
Here we combine multiple lines of evidence to firmly establish a role for the Wallerian 101 
pathway in axon degeneration caused by mitochondrial depolarisation in the 102 
absence of a physical injury. We also corroborate these findings using an in vivo 103 
genetic model of mitochondrial dysfunction, reporting a neuroprotective role of 104 
regulators of Wallerian degeneration in dopaminergic neuron loss in Pink1 mutant 105 
flies.    106 
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RESULTS 107 
Multiple regulators of the Wallerian pathway rescue axon degeneration caused 108 
by mitochondrial depolarisation 109 
The mitochondrial uncoupler CCCP is widely used to trigger mitochondrial 110 
depolarisation and assess the effects of mitochondrial impairment on cellular viability 111 
(Ly et al., 2003). Previous work by us and others demonstrated that sympathetic and 112 
sensory primary neurons exposed to CCCP undergo disruption of mitochondrial 113 
membrane potential and axon degeneration (Loreto et al., 2015; Summers et al., 114 
2014), providing a good experimental model to study mitochondrial dysfunction 115 
leading to axon degeneration. 116 
A dose-response experiment in superior cervical ganglion (SCG) neurons confirmed 117 
previous observations and allowed us to determine the most appropriate 118 
concentration of CCCP to use across the study. 50µM CCCP induces full 119 
mitochondrial depolarization within minutes after its addition (Loreto et al., 2015) and 120 
a dramatic depletion of ATP levels within the first 2 hr (Fig. 1A). Importantly, it 121 
consistently promoted neurite degeneration when measured at 24 hr post-application 122 
(Fig. 1B-G).  123 
We then tested whether this degenerative process could be rescued by regulators of 124 
the Wallerian pathway. Consistent with previous studies (Summers et al., 2014), we 125 
found that Sarm1-/- SCG neurites were strongly protected against CCCP toxicity (Fig. 126 
1D,E). WLDS expression was highly protective too at this concentration (Fig. 1F,G).  127 
Our findings demonstrate that the degeneration of axons following mitochondrial 128 
depolarisation can be delayed by multiple regulators of the Wallerian pathway.  129 
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Mitochondrial depolarisation leads to depletion of axonal NMNAT2 130 
NMNAT2 depletion in axons has been proposed as an initial step that triggers the 131 
activation of the Wallerian pathway (Gilley and Coleman, 2010; Gilley et al., 2015; 132 
Loreto et al., 2015; Walker et al., 2017). We therefore tested whether CCCP 133 
treatment led to NMNAT2 depletion in neurites (which were uninjured until 134 
immediately prior to harvesting separately from their cell bodies) and found that 135 
levels of this protein in neurites rapidly decline from 2 hr after CCCP addition (Fig. 136 
2A,B). Loss of NMNAT2 occurred before any visible morphological damage to 137 
neurites (Fig. 2C), also confirmed by the absence of changes to E-actin levels (Fig. 138 
2A). Levels of SCG10, another short-lived protein comigrating with NMNAT2 (Milde 139 
et al., 2013) and involved in Wallerian degeneration (Shin et al., 2012) and sporadic 140 
ALS (Melamed et al., 2019), declined with a similar timecourse (Fig. 2A,B). 141 
We have recently reported that lowering the expression of NMNAT2 increases 142 
axonal vulnerability to several stresses (Gilley et al., 2019). To test whether lowering 143 
NMNAT2 expression impairs the ability to withstand mitochondrial impairment, SCG 144 
neurons from mice with around 60% (Nmnat2+/gtE) and 30% (Nmnat2gtBay/gtE) of wild 145 
type Nmnat2 mRNA levels in whole brain (Gilley et al., 2019) were exposed to 146 
CCCP. We found a significant acceleration of the degeneration process compared to 147 
wild type neurons, with clear morphological damage appearing as early as 4 hr in 148 
Nmnat2gtBay/gtE neurites (Fig. 2D,E).  149 
These data suggest that mitochondrial uncoupling activates the Wallerian pathway at 150 
an early step and, together with the protection afforded by WLDS (Fig. 1F,G), they 151 
indicate that axonal NMNAT levels modulate axon survival after mitochondrial 152 
depolarisation.  153 
NMNAT2 depletion reflects impairment of both axonal transport and synthesis  154 
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We next investigated the cause of NMNAT2 depletion after CCCP treatment. Being a 155 
labile protein with a half-life of less than an hour (Milde et al., 2013), any cellular 156 
process that impairs its replenishment in axons would lead to a rapid decrease in 157 
axonal levels. Two potential mechanisms are a deficiency in axonal transport and/or 158 
altered synthesis, both of which are ATP-dependent. The finding that NMNAT2 159 
levels also declined in the cell body/ganglia fraction after 4-8 hr of CCCP addition 160 
(Fig. 3A,B) suggests that synthesis of the protein is impaired (although enhanced 161 
protein degradation cannot be ruled out). However, the NMNAT2 decrease in the cell 162 
body fraction was much less marked than that in neurites (Fig. 2A,B), suggesting 163 
that impaired protein synthesis is not the only mechanism contributing to the 164 
depletion in the neurites. SCG10 levels in the cell body fraction, instead, did not vary 165 
significantly (Fig. 3A,B). 166 
We next explored whether CCCP alters NMNAT2 axonal transport. We microinjected 167 
GFP-tagged NMNAT2 and followed changes in its axonal transport parameters. We 168 
found a significant reduction of the percentage of motile NMNAT2 vesicles at 4 and 8 169 
hr after CCCP addition (Fig. 3C,D). This may also explain the slight recovery of 170 
NMNAT2 levels in cell bodies at 8 hr after CCCP addition following the decline at 4 171 
hr (Fig. 3A,B), as any NMNAT2 that is synthesised would be less efficiently 172 
transported into neurites and would accumulate in cell bodies instead. The overall 173 
reduction in axonal transport of NMNAT2 appeared to be a result of a combination of 174 
impaired anterograde, retrograde and bidirectional transport, although separately 175 
none of the individual parameters reached statistical significance (Fig. 3E).  176 
Thus, reduced axonal transport of NMNAT2 and reduced synthesis and/or enhanced 177 
degradation combine to reduce axonal NMNAT2 levels after CCCP treatment. 178 
Changes in the NMN/NAD ratio following CCCP administration 179 
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We have shown that NMNAT2 depletion leads to accumulation of its substrate, 180 
NMN, which we suggest promotes axon degeneration (Di Stefano et al., 2015, 2017; 181 
Loreto et al., 2015), as well as to NAD depletion, which also plays an important role 182 
(Essuman et al., 2017; Sasaki et al., 2016) (Fig. 4A). Thus, changes in NMN/NAD 183 
ratio is an additional indicator of Wallerian pathway activation. We previously 184 
reported a marked increase of NMN levels in injured sciatic nerves in vivo (Di 185 
Stefano et al., 2015, 2017). Sasaki and colleagues recently showed a transient 186 
increase in NMN levels in sensory neurons after axotomy also in vitro (Sasaki et al., 187 
2016). However, selecting the correct time points is difficult due to the substantial 188 
cellular material required for the analysis and the rapid degeneration process which 189 
compromises the integrity of the plasma membrane, making any measurement 190 
unreliable. We therefore tested whether NMN accumulates and NAD declines 191 
following mitochondrial depolarisation in Sarm1-/- SCG neurons, where the 192 
degeneration process following CCCP administration is strongly delayed (Fig. 1D,E). 193 
We looked at 12 hr after CCCP treatment, when wild-type neurites showed the first 194 
signs of degeneration (Fig. 2C,D), reasoning that an increase in NMN levels should 195 
have already occurred. We found a 2-fold increase in NMN levels and a more 196 
modest decrease in NAD levels in neurites resulting in a robust increase in the 197 
NMN/NAD ratio (Fig. 4B) (Fig. S1A), consistent with the predicted effects of 198 
NMNAT2 loss. In contrast, changes in the cell bodies were much more modest (Fig. 199 
4C) (Fig. S1B), consistent with levels of NMNAT2 in the soma being less affected 200 
after CCCP administration (Fig. 3A,B) and with the presence of nuclear NMNAT1, 201 
which will contribute to NMN and NAD homeostasis in this compartment. 202 
Several lines of evidence suggest that NMN accumulation is not simply a marker but 203 
is a trigger of axon degeneration. Blocking NMN accumulation with FK866, an 204 
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inhibitor of the NMN-synthesizing enzyme NAMPT (Fig. 4A), delays Wallerian 205 
degeneration. Exogenous administration of NMN restores its accumulation in the 206 
presence of FK866, reverting the protection (Di Stefano et al., 2015; Loreto et al., 207 
2015). Also scavenging NMN with expression of bacterial enzyme NMN deamidase, 208 
which converts NMN into NaMN (Fig. 4A), results in strong protection of injured 209 
axons in mouse primary neurons and in vivo in mice and zebrafish (Di Stefano et al., 210 
2015, 2017; Loreto et al., 2015). We therefore tested whether NMN accumulation 211 
also promotes axon degeneration after CCCP administration. We first confirmed that 212 
the levels of NAMPT were not affected by CCCP treatment (Fig. 5A,B). This is 213 
important since NAMPT expression is required for NMN synthesis, which results in 214 
the accumulation of NMN in the absence of NMNAT2. We then tested whether 215 
blocking NMN synthesis with FK866 delays CCCP-induced axon degeneration. As 216 
with axon degeneration after axotomy (Di Stefano et al., 2015), FK866 treatment 217 
strongly delayed neurite degeneration following CCCP administration. Of note, co-218 
administration of exogenous NMN reverted FK866-induced protection (Fig. 5C,D). In 219 
contrast to our previous findings (Di Stefano et al., 2015), some studies reported a 220 
protective effect of NMN against axotomy-induced axon degeneration (Sasaki et al., 221 
2006), possibly due to differences in incubation time of NMN before transection. 222 
Importantly, we confirmed that NMN had no protective effect on the degeneration 223 
process when added together with CCCP (Fig. 5E,F). NMNAT2 depletion still 224 
occurred in neurites protected by FK866, consistent with its expected protective 225 
action downstream of NMNAT2 loss in this situation (Fig. S2A) (Di Stefano et al., 226 
2015). FK866 conferred full protection also when added up to 8 hr after CCCP 227 
addition (when NMNAT2 levels in neurites are already dramatically reduced) and 228 
halted the progression of the degeneration when added 12 hr after CCCP (when 229 
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neurites appear already damaged) (Fig. S2B,C). This suggests that activation of the 230 
pathway might be reversible, or at least the existence of a time window after 231 
mitochondrial dysfunction when it can be prevented, which is important in the context 232 
of therapeutic intervention in human diseases. 233 
Taken together, these data further support a pro-degenerative role of NMN and are 234 
an additional confirmation that CCCP causes axon degeneration through the 235 
activation of the Wallerian pathway. 236 
Highwire deletion rescues loss of dopaminergic neurons in Pink1 Drosophila 237 
mutants 238 
To validate our findings in an in vivo model where mitochondrial dysfunction is 239 
caused by a genetic mutation, we employed a Drosophila mutant with a loss-of-240 
function mutation in the PD-associated gene Pink1 (Pink1B9). Pink1 is involved in 241 
mitochondrial quality control and mutations in this protein are linked to early-onset 242 
recessive PD (Pickrell and Youle, 2015; Valente et al., 2001, 2004). Loss of Pink1 in 243 
flies leads to severe mitochondrial defects resulting in, among other phenotypes, 244 
loss of dopaminergic neurons (in the PPL1 cluster), locomotor deficits and reduced 245 
lifespan (Clark et al., 2006; Hewitt and Whitworth, 2017; Park et al., 2006; Tain et al., 246 
2009). The Wallerian pathway is evolutionary conserved, with several orthologous 247 
genes controlling axon degeneration both in mammals and flies (Freeman, 2014) 248 
(Fig. S3). As ubiquitous dSarm deletion is lethal in Drosophila, we instead opted to 249 
assess the effects of Highwire mutation on the Pink1B9 phenotype. Highwire, and its 250 
mammalian ortholog PHR1, are E3 ubiquitin ligases that target Drosophila NMNAT 251 
(dNMNAT) and NMNAT2, respectively, for proteasomal degradation and 252 
Highwire/PHR1 depletion appears to delay axon degeneration after axotomy by 253 
increasing levels and/or stabilising dNMNAT/NMNAT2, preventing the activation of 254 
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the Wallerian pathway at an early step (Babetto et al., 2013; Xiong et al., 2012) (Fig. 255 
S3).  256 
We first tested whether Highwire deficiency (Hiw'N) could rescue the loss of 257 
dopaminergic neurons in the PPL1 cluster (Fig. 6A) in Pink1B9 flies. As Highwire 258 
mutants display synaptic overgrowth during development at the neuromuscular 259 
junction (Wan et al., 2000), we first confirmed that the number of dopaminergic 260 
neurons in the PPL1 cluster did not differ from wild-type flies (Fig. 6B,C). Importantly, 261 
Highwire deletion rescued the loss of dopaminergic neurons in the PPL1 cluster (Fig. 262 
6B,C). Highwire deletion also significantly prolonged the lifespan of Pink1B9 flies (Fig. 263 
6D), but was not sufficient to rescue climbing and flying ability (Fig. 6E,F), likely due 264 
to the widespread muscle degeneration that is also seen in Pink1B9 flies (Clark et al., 265 
2006; Tain et al., 2009). Modulation of the Wallerian pathway thus appears to be 266 
protective against neurodegeneration caused by non-toxin models of mitochondrial 267 
disruption in flies.  268 
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DISCUSSION 269 
The data presented here support an involvement of the Wallerian pathway in 270 
disorders involving mitochondrial dysfunction. First, acute mitochondrial 271 
depolarisation by CCCP leads to axon degeneration, in the absence of a physical 272 
injury, through the same pathway that regulates Wallerian degeneration. It does so 273 
by impairing axonal transport and synthesis (or stimulating degradation) of the 274 
axonal survival enzyme NMNAT2, leading to substantially reduced levels in neurites 275 
which increase the NMN/NAD ratio and trigger SARM1-dependent axon 276 
degeneration. In addition, neuroprotection of dopaminergic neurons conferred by 277 
Highwire deletion in flies carrying mutant Pink1 suggests a wider relevance of the 278 
Wallerian pathway to different types of mitochondrial insults in vivo. 279 
Our previous work and that of others suggest a minor contribution of mitochondria to 280 
the late stages of Wallerian degeneration after axon transection (Kitay et al., 2013; 281 
Loreto et al., 2015), mainly through the opening of mitochondria permeability 282 
transition pore and release of Ca2+ into the cytoplasm (Barrientos et al., 2011; 283 
Villegas et al., 2014). We now show that mitochondrial dysfunction can impact on the 284 
Wallerian pathway in a second way, activating it at an early step upstream of 285 
NMNAT2. Crucially, like FK866-protected axons (Loreto et al., 2015), Sarm1-/- and 286 
WldS axons can be kept morphologically intact for days despite fully depolarised 287 
mitochondria (this study and (Loreto et al., 2015; Summers et al., 2014)). This 288 
indicates that WLDS expression and SARM1 deficiency confer protection 289 
downstream of mitochondrial impairment (Fig. 7), rather than directly impacting on 290 
mitochondrial health.  291 
The relevance of the Wallerian pathway beyond its role after axotomy is now widely 292 
accepted and mitochondrial depolarisation can now be added to a growing list of 293 
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non-axotomy insults causing Wallerian-like degeneration, including toxicity caused 294 
by chemotherapy agents, chemicals disruption of the nigrostriatal pathway, protein 295 
synthesis inhibition and NGF withdrawal (Conforti et al., 2014). Importantly, most of 296 
these studies used either WLDS expression or Sarm1 deletion as means to assess 297 
the involvement of Wallerian-like degeneration. However, these proteins are likely to 298 
have additional, non-Wallerian pathway functions and could thus confer a protective 299 
phenotype independently of the Wallerian pathway. For example, WLDS protection 300 
against neuropathy and retinopathy in a streptozotocin-induced mouse model of 301 
diabetes is linked to a rescue of pancreatic islets (Zhu et al., 2011), likely through a 302 
mechanism that is unrelated to its role in axons. Recent steps forward in the 303 
understanding of the molecular mechanisms of axon degeneration revealed a well-304 
defined pathway of axon death, with the identification of crucial mechanistic links 305 
between NMNAT2 and SARM1 (Gilley et al., 2015, 2017). The knowledge of a core 306 
mechanistic pathway allows multiple stages to be probed when seeking to establish 307 
a role for the Wallerian pathway in non-axotomy insults and diseases. Here, we 308 
followed this approach focusing on NMNAT2 levels, changes in NMN/NAD ratio and 309 
protection conferred by WLDS expression and Sarm1 deletion. This is the first 310 
demonstration of Wallerian pathway involvement at multiple steps in a non-axotomy 311 
axonal stress. 312 
A next crucial question is whether the activation of the Wallerian pathway contributes 313 
to neurodegenerative disorders caused by mitochondrial dysfunction. CCCP is 314 
widely used to impair mitochondrial function and has proven instrumental for 315 
understanding the role of mitochondria in a number of physiological and non-316 
physiological cellular processes. However, it remains unclear how much its potent 317 
and acute mitochondrial toxicity reflects chronic mitochondrial dysfunction in human 318 
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pathologies. The strong protection achieved by blocking the Wallerian pathway is 319 
remarkable, but the extent of mitochondrial damage in neurodegenerative disorders 320 
is likely to be milder. The neuroprotection in vivo in Pink1 mutant flies represents a 321 
first indication of the possible wider relevance of the Wallerian pathway to other 322 
mitochondrial insults in vivo, although the use of alternative means to impair 323 
mitochondria could provide further understanding of the mechanisms involved. The 324 
protection of neuronal soma in Pink1B9 flies could be secondary to rescue of axon 325 
loss. Conversely, Drosophila only has one NMNAT isoform (compared to three in 326 
mammals) and so a reduction in dNMNAT levels would likely cause a more profound 327 
damage to the whole cell, rather than predominantly affecting axons (as it is the case 328 
with the major axonal isoform, NMNAT2, in mammals). Finally, we cannot fully rule 329 
out the possibility that other actions of Highwire contribute to these observations. 330 
Among a number of neurodegenerative disorders associated with mitochondrial 331 
dysfunction, the link between PD and axon loss is particularly important. PD involves 332 
preferential loss of substantia nigra pars compacta dopaminergic neurons. These 333 
neurons have extremely long and branched axons which are lost early in PD patients 334 
(Matsuda et al., 2009; Tagliaferro and Burke, 2016), and, as such, may be more 335 
vulnerable to axonal stresses. Wallerian-like degeneration has also been implicated 336 
in other PD models, with WLDS protecting after MPTP and 6-hydroxydopamine 337 
administration (Cheng and Burke, 2010; Hasbani and O’Malley, 2006; Sajadi et al., 338 
2004), and with neuroprotection in Pink1 mutant flies by Highwire deficiency that can 339 
now be added to the list. However, more comprehensive studies in genetic and 340 
chronic models of PD in mammals will be needed to establish whether the Wallerian 341 
pathway plays a causative role in PD pathology or simply increases susceptibility to 342 
disease. Interestingly, we also show that lower levels of NMNAT2 make neurites 343 
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more vulnerable to the consequences of CCCP-induced mitochondrial depolarisation 344 
and, as NMNAT2 mRNA levels have been reported to vary hugely in the human 345 
population (up to 50-fold differences) (Ali et al., 2016), some individuals might thus 346 
be at a much higher risk of mitochondrial disorders. 347 
To conclude, we show that acute mitochondrial impairment induced by CCCP leads 348 
to NMNAT2 depletion and subsequent activation of the Wallerian pathway (Fig. 7), 349 
and that loss of dopaminergic neurons as a result of mitochondrial dysfunction in 350 
flies with Pink1 loss-of-function mutation can be prevented by modulation of the 351 
Wallerian pathway by Highwire deletion. This study provides mechanistic insights on 352 
how mitochondrial dysfunction leads to axon degeneration and identifies the 353 
Wallerian pathway as a potential contributor to axon pathology in mitochondrial 354 
disorders. It is now important to test the role of the pathway in models that more 355 
closely replicate human mitochondrial diseases.    356 
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MATERIALS AND METHODS 357 
All studies conformed to the institution’s ethical requirements in accordance with the 358 
1986 Animals (Scientific Procedures) Act. 359 
Primary neuronal cultures 360 
C57BL/6J or CD1 (referred to as wild-type, Charles River, UK), WldS, Nmnat2+/+, 361 
Nmnat2+/gtE, Nmnat2gtBay/gtE and Sarm1-/- mouse SCG explants were dissected from 362 
P0-2 pups. Explants were cultured in 35 mm tissue culture dishes pre-coated with 363 
poly-L-lysine (20 µg/ml for 1 hr; Sigma) and laminin (20 µg/ml for 1 hr; Sigma) in 364 
Dulbecco's Modified Eagle's Medium (DMEM, Gibco) with 1% penicillin/streptomycin, 365 
100 ng/ml 7S or 50 ng/ml 2.5S NGF (all Invitrogen) and 2% B27 (Gibco). 4 µM 366 
aphidicolin (Merck) was used to reduce proliferation and viability of small numbers of 367 
non-neuronal cells. For cultures of dissociated SCG neurons, wild-type SCG 368 
explants were incubated in 0.025% trypsin (Sigma) in PBS (without CaCl2 and 369 
MgCl2) (Sigma) for 30 min followed by incubation with 0.2% collagenase type II 370 
(Gibco) in PBS for 20 min. Ganglia were then gently dissociated using a pipette. 371 
Dissociated neurons were plated in a poly-L-lysine and laminin-coated area of ibidi 372 
μ-dishes (Thistle Scientific) for microinjection experiments. Dissociated cultures were 373 
maintained as explant cultures except that B27 was replaced with 10% fetal bovine 374 
serum (Sigma). Culture media was replenished every 3 days. Neurites were allowed 375 
to extend for 7 days before performing the experiments. 376 
Drug treatments 377 
Uncut SCG neurons were treated with CCCP or vehicle (DMSO) just prior to imaging 378 
(time 0 hr). Unless specified, FK866 (kind gift of Prof. Armando Genazzani, 379 
University of Novara) and NMN (Sigma) were added at the same time as CCCP. The 380 
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incubation time and the drug concentration used for every experiment are indicated 381 
in the figures and/or figure legends. 382 
Acquisition of phase contrast images and quantification of axon degeneration 383 
Phase contrast images were acquired on a DMi8 upright fluorescence microscope 384 
(Leica microsystems) coupled to a monochrome digital camera (Hammamatsu 385 
C4742-95) or on a Zeiss TIRF microscope coupled to an EMCCD (Photometrics 386 
PVCam) camera using Axiovision software (Carl Zeiss Inc.). The objectives used 387 
were HCXPL 20X/0.40 Corr and Zeiss EC Plan Neofluar 20X/0.5 NA. The axon 388 
degeneration index (Sasaki et al., 2009) was determined using an ImageJ plugin 389 
(Schneider et al., 2012) (http://rsb.info.nih.gov/ij/download.html) which calculates the 390 
ratio of fragmented axon area over total axon area after binarization of the pictures 391 
and subtraction of the background.  392 
Determination of ATP levels 393 
For measurement of ATP levels, dissociated SCG neurons were plated in 96-well 394 
plates at the same density. ATP measurements were performed with the ATPlite 395 
Luminescence Assay System (PerkinElmer). Two technical repeats were performed 396 
per each condition for every experiment. Data are expressed as % relative to DMSO 397 
control.  398 
Western blot 399 
Following treatment with CCCP, SCG ganglia were separated from their neurites 400 
with a scalpel. Neurites originating from 15 ganglia were collected per condition, 401 
washed in ice-cold PBS containing protease inhibitors (Sigma), and lysed directly in 402 
15 µl 2x Laemmli buffer containing 10% 2-Mercaptoethanol (Sigma). The remaining 403 
15 ganglia were also collected and lysed. For NMNAT2 immunoblots, 14 µl of protein 404 
samples were loaded on a 12% SDS polyacrylamide gel. For SCG10 and NAMPT 405 
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immunoblots, 1:15 dilutions of the original samples were loaded on a 12% SDS 406 
polyacrylamide gel. Membranes were blocked for 3 hr in 5% milk in TBS (50 mM 407 
Trizma base and 150 mM NaCl, PH 8.3, both Sigma) plus 0.05% Tween-20 (Sigma) 408 
(TBST), incubated overnight with primary antibody in 5% milk in TBST at 4°C and 409 
subsequently washed in TBST and incubated for 1 hr at room temperature with 410 
HRP-linked secondary antibody (Bio-Rad) in 5% milk in TBST. Membranes were 411 
washed, treated with ECL (Enhanced Chemiluminescence detection kit; 412 
Thermofisher) and imaged with Uvitec Alliance imaging system. The following 413 
primary antibodies were used: mouse anti-NMNAT2 (WH0023057M1 Sigma, 2 414 
µg/ml), mouse anti-NAMPT (clone OMNI 379, Cayman Chemical Company, 1:2000) 415 
and rabbit anti-SCG10 (10586-1-AP Proteintech, 1:3000). Mouse anti β-actin was 416 
used as a loading control (A5316 Sigma, 1:5000). Quantification of band intensity 417 
was determined by densitometry using ImageJ.  418 
NMNAT2 axonal transport 419 
Dissociated SCG neurons were microinjected using a Zeiss Axiovert S100 420 
microscope with an Eppendorf FemtoJet microinjector and Eppendorf TransferMan® 421 
micromanipulator. Plasmids were diluted in 0.5x PBS (without CaCl2 and MgCl2) and 422 
filtered using a Spin-X filter (Costar). The mix was injected directly into the nuclei of 423 
SCG neurons using Eppendorf Femtotips. Approximately 100 neurons were injected 424 
per dish. Injected plasmids were allowed to express for 16 hr before CCCP 425 
treatment. Plasmids were injected at the following concentrations: 30 ng/µl 426 
NMNAT2-EGFP, 30 ng/µl pDsRed2-N1. Time-lapse imaging of axonal transport was 427 
performed on an Olympus IX70 imaging system with 100X/1.35 Oil objective. During 428 
imaging, cell cultures were maintained at 37°C and 5% CO2 in an environment 429 
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chamber. Images were captured at 4 frames per sec for 2 min. Three neurites per 430 
condition were imaged in every individual experiment. 431 
Determination of NMN and NAD levels 432 
Following treatment with CCCP, Sarm1-/- SCG ganglia were separated from their 433 
neurites with a scalpel. Neurites and cell bodies were washed in ice-cold PBS and 434 
rapidly frozen in dry ice and stored at −80 °C until processed for measuring NMN 435 
and NAD. Briefly, pyridine and adenine nucleotides were extracted by sonication in 436 
HClO4 in the presence of cAMP (as internal standard) and subsequently analysed by 437 
ion pair C18-HPLC chromatography and by spectrofluorometric HPLC analysis after 438 
derivatization with acetophenone (Mori et al., 2014). The levels of NMN and NAD 439 
were normalised to protein levels.  440 
Drosophila experiments 441 
Newly enclosed flies were collected daily and separated by sex into vials of 20-35 442 
flies for aging and experimental use. Genotypes used are w1118 (wild-type), Pink1B9, 443 
Hiw'N and Hiw'N Pink1B9. All flies were maintained at a constant 25qC temperature 444 
and humidity, in plastic vials with standard agar/cornmeal/yeast feed. Flies were 445 
exposed to a 12 hr light-dark cycle. All experiments were conducted on male flies. 446 
For PPL1 dopaminergic neuron staining, fly brains were dissected in cold 1x PBS 447 
and fixed in 4% paraformaldehyde-PBS (Sigma) for 30 min. Samples were washed 448 
in 1x PBS with 0.3% Triton X-100 (Sigma) and blocked for 1 hr at room temperature 449 
in 1x PBS with 0.3% Trition X-100 and 1% BSA (Sigma). Brains were incubated in 450 
primary antibody for 72 hr. After washing and incubation in a fluorescent secondary 451 
antibody solution for 4 hr, samples were mounted between two coverslips in ProLong 452 
diamond antifade mountant (ThermoFisher). Confocal images were acquired on a 453 
Leica microscopy system and blinded for analysis. Antibodies used were mouse anti-454 
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Tyrosine Hydroxylase 1:100 (22941, Immunostar Inc.) and secondary anti-mouse 455 
IgG (H+L) Alexa Fluor 488 (A11034, ThermoFisher). Flight assay was performed as 456 
previously described (Agrawal and Hasan, 2015). Briefly, flies were anaesthetised on 457 
ice for 5 min; the flat of a 30G 1” needle (Sigma) was attached to the anterior notum 458 
of a fly just posterior to the neck using clear nail varnish, leaving flight muscles 459 
unimpeded. Flies were given 15 min to recover. Needles were fixed in place under a 460 
video microscope. If required, a gentle mouth-blown puff of air was used to stimulate 461 
flight and the flying time was recorded for 30 sec. This was repeated 3 times per fly 462 
and the average of time spent in flight was calculated for each condition. For 463 
climbing assays, flies were gently transferred to fresh empty polystyrene vials 464 
without anaesthesia with a maximum density of 25 flies per vial. Groups of up to 6 465 
vials were inserted into the RING device and after 5 min for the flies to adjust to the 466 
environmental change the device was tapped three times to settle flies to the bottom 467 
of the vials. 5 sec after the last tap, a picture was taken to assess the height climbed. 468 
Maximum height achieved was graded into 5 mm intervals, flies that climbed less 469 
than 5 cm were scored zero, and any fly that exceeded 5 cm was awarded the 470 
maximum score. This was repeated 3 times at 60 sec intervals and an average score 471 
given for that vial.  472 
Statistical analysis  473 
Appropriate statistical testing of data was performed using Prism 474 
(GraphPad Software, La Jolla, USA). ANOVA with Tukey’s, Sidak’s or Bonferroni’s 475 
post hoc correction (as applicable), and log-rank (Mantel-Cox) test were used in 476 
this study. The n numbers in each individual experiment and the tests used are 477 
described in the figure legends. A p value < 0.05 was considered significant (****, 478 
p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05; NS, non-significant).  479 
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FIGURE LEGENDS 651 
Figure 1. Regulators of the Wallerian pathway rescue axon degeneration 652 
caused by mitochondrial depolarisation 653 
(A) ATP levels in wild-type SCG dissociated cultures after treatment with CCCP. 654 
Data are normalised to DMSO control at each time point (Mean±SEM; n=4; two-way 655 
ANOVA followed by Sidak post-hoc test; ****, p<0.0001). (B) Representative phase 656 
contrast images of neurites from wild-type SCG explant cultures treated with 657 
increasing concentrations of CCCP. (C) Quantification of the degeneration index in 658 
experiments described in (B) from 3 fields per sample in 2 independent experiments 659 
(Mean±SEM; n=2). (D) Representative phase contrast images of neurites from wild-660 
type and Sarm1-/- SCG explant cultures at the indicated time points after CCCP 661 
treatment. (E) Quantification of the degeneration index in experiments described in 662 
(D) from 3 fields per sample in 4 independent experiments (Mean±SEM; n=4; two-663 
way ANOVA followed by Tukey post-hoc test; ****, p<0.0001. Statistical significance 664 
shown relative to +50 µM CCCP). (F) Representative phase contrast images of 665 
neurites from wild-type and Wlds SCG explant cultures at the indicated time points 666 
after CCCP treatment. (G) Quantification of the degeneration index in experiments 667 
described in (F) from 3 fields per sample in 4 independent experiments (Mean±SEM; 668 
n=4; two-way ANOVA followed by Tukey post-hoc test; ****, p<0.0001. Statistical 669 
significance shown relative to +50µM CCCP). 670 
Figure 2. Mitochondrial depolarisation leads to depletion of axonal NMNAT2 671 
(A) Representative immunoblots of wild-type SCG neurite extracts probed for 672 
NMNAT2, SCG10 and β-actin (loading control) at the indicated time points after 673 
CCCP treatment. (B) Quantification of normalised NMNAT2 and SCG10 levels (to β-674 
actin) is shown, with data presented relative to DMSO control (Mean±SEM; n=3-4; 675 
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one-way ANOVA followed by Bonferroni post-hoc test; ***, p<0.001; **, p<0.01; *, 676 
p<0.05). (C) Representative phase contrast images showing morphologically intact 677 
neurites at the time points used in (A). (D) Representative phase contrast images of 678 
neurites from wild-type-Nmnat2+/+, Nmnat2+/gtE (a60% expression), Nmnat2gtBay/gtE 679 
(a30% expression) SCG explant cultures at the indicated time points after CCCP 680 
treatment. (E) Quantification of the degeneration index in experiments described in 681 
(D) from 3 fields per sample in 4 independent experiments (Mean±SEM; n=4; two-682 
way ANOVA followed by Tukey post-hoc test; ****, p<0.0001; ***, p<0.001; **, 683 
p<0.01. Statistical significance shown relative to Nmnat2+/+ +50µM CCCP).  684 
Figure 3. NMNAT2 depletion reflects impairment of both axonal transport and 685 
synthesis  686 
(A) Representative immunoblot of wild-type SCG cell bodies/ganglia extracts probed 687 
for NMNAT2, SCG10 and β-actin (loading control) at the indicated time points after 688 
CCCP treatment. (B) Quantification of normalised NMNAT2 and SCG10 levels (to β-689 
actin) is shown, with data presented relative to DMSO control (Mean±SEM; n=4; 690 
one-way ANOVA followed by Bonferroni post-hoc test; ****, p<0.0001; **, p<0.01; 691 
NS, non-significant). (C) Representative kymographs of wild-type SCG dissociated 692 
cultures expressing NMNAT2-EGFP. (D) Quantification of the % of motile NMNAT2 693 
at the indicated time points after CCCP treatment from 3 neurites per condition in 4 694 
independent experiments (Mean±SEM; n=4; two-way ANOVA followed by Sidak 695 
post-hoc test; *, p<0.05. NS, non-significant). (E) Quantification of the % of motile 696 
bidirectional, anterograde and retrograde NMNAT2 at the indicated time points after 697 
CCCP treatment from 3 neurites per condition in 4 independent experiments 698 
(Mean±SEM; n=4; two-way ANOVA followed by Sidak post-hoc test; NS, non-699 
significant). 700 
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Figure 4. Changes in the NMN/NAD ratio following CCCP administration 701 
(A) Schematic representation of NAD salvage pathway from nicotinamide and points 702 
at which FK866 and bacterial NMN deamidase will act (NAM, nicotinamide; NaMN, 703 
nicotinic acid mononucleotide; NMN, nicotinamide mononucleotide; NAD, 704 
nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; 705 
NMNAT, nicotinamide mononucleotide adenylyltransferase). (B,C) NMN and NAD 706 
levels and NMN/NAD ratios in neurite (B) and cell body/ganglia (C) fractions from 707 
Sarm1-/- SCG explant cultures at the indicated time points after CCCP treatment 708 
(Mean±SEM; n=5; one-way ANOVA followed by Bonferroni post-hoc test; ****, 709 
p<0.0001; **, p<0.01; *, p<0.05. Statistical significance shown relative to 12 hr 710 
DMSO). 711 
Figure 5. Inhibition of NMN synthesis protects neurites against CCCP toxicity 712 
(A,B) Representative immunoblot of wild-type SCG neurite extracts probed for 713 
NAMPT and β-actin (loading control) at the indicated time points after CCCP 714 
treatment. Quantification of normalised NAMPT levels (to β-actin) is shown, with data 715 
presented relative to DMSO control (Mean±SEM; n=4; one-way ANOVA followed by 716 
Bonferroni post-hoc test; NS, non-significant). (C) Representative phase contrast 717 
images of neurites from wild-type SCG explant cultures at the indicated time points 718 
after CCCP, FK866 and NMN treatment. Where indicated, FK866 and NMN were 719 
added at the same time of CCCP. (D) Quantification of the degeneration index in 720 
experiments described in (C) from 3 fields per sample in 4 independent experiments 721 
(Mean±SEM; n=4; two-way ANOVA followed by Tukey post-hoc test; ****, p<0.0001. 722 
Statistical significance shown relative to +50µM CCCP). (E) Representative phase 723 
contrast images of neurites from wild-type SCG explant cultures at the indicated time 724 
points after CCCP and NMN treatment. (F) Quantification of the degeneration index 725 
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in experiments described in (E) from 3 fields per sample in 4 independent 726 
experiments (Mean±SEM; n=4; two-way ANOVA followed by Tukey post-hoc test). 727 
Figure 6. Highwire deletion rescues loss of dopaminergic neurons in Pink1 728 
Drosophila mutants 729 
(A) Schematic image of a Drosophila brain with the PPL1 cluster of dopaminergic 730 
neurons shown in green (‘Created with BioRender’). (B) Representative images of 731 
adult Drosophila (20 days old) brains stained with anti-TH antibody. The PPL1 732 
cluster of dopaminergic neurons is shown. (C) Quantification of the number of 733 
dopaminergic neurons per PPL1 cluster (Mean±SEM; n=16-25; one-way ANOVA 734 
followed by Tukey post-hoc test; **, p<0.01). (D) Lifespan curves of wild-type, Hiw'N, 735 
Pink1B9, Hiw'N Pink1B9 flies (n>130 flies per condition; log-rank (Mantel-Cox) test. 736 
****, p<0.0001). (E,F) Analysis of climbing and flying ability of 7 days old flies of the 737 
indicated genotypes (Mean±SEM; n=3 climbing, n=9 flying; one-way ANOVA 738 
followed by Tukey post-hoc test; NS, non-significant). 739 
Figure 7. Mitochondrial dysfunction as an upstream signal activating the 740 
Wallerian pathway 741 
Schematic representation of the Wallerian pathway (‘Created with BioRender’). Injury 742 
and mitochondrial impairment act as two independent insults resulting in the 743 
activation of the Wallerian pathway. 744 
Figure S1. 745 
(A,B) Relative changes in NMN, NAD and NMN/NAD ratios in separate neurite (A) 746 
and cell bodies/ganglia (B) fractions from Sarm1-/- SCG explant cultures at the 747 
indicated time points after CCCP treatment (Mean±SEM; n=5; one-way ANOVA 748 
followed by Bonferroni post-hoc test; ****, p<0.0001; **, p<0.01; NS, non-significant. 749 
Statistical significance shown relative to 12 hr DMSO). 750 
 31 
Figure S2.  751 
(A) Representative immunoblot of wild-type SCG neurite extracts probed for 752 
NMNAT2 and β-actin (loading control) 4 hr after CCCP, FK866 and NMN treatment. 753 
Quantification of normalised NMNAT2 and SCG10 levels (to β-actin) is shown, with 754 
data presented relative to DMSO control (Mean±SEM; n=2). (B) Representative 755 
phase contrast images of neurites from wild-type SCG explant cultures at the 756 
indicated time points after CCCP treatment. Where indicated, FK866 was added 757 
either at the same time of CCCP (0 hr) or 4, 8, 12 hr after CCCP addition. (C) 758 
Quantification of the degeneration index in experiments described in (B) from 3 fields 759 
per sample in 3 independent experiments (Mean±SEM; n=3; two-way ANOVA 760 
followed by Tukey post-hoc test; ****, p<0.0001; ***, p<0.001; NS, non-significant. 761 
Statistical significance shown relative to +50µM CCCP). 762 
Figure S3.   763 
The Wallerian pathway is evolutionary conserved in flies and mammals. Highwire 764 
position in the pathway is shown (‘Created with BioRender’). 765 
50µm




















0 24 48 72 








































































































































































Hours after CCCP addition 









































































































































































































































































































































































































C Hours after drug addition 




















































+50µM CCCP +100nM FK866 +1mM NMN


























0 24 48 




































































Hours after CCCP addition 
+50µM CCCP





























































































































NMN and NMN/NAD ratio









Click here to download Supplementary Material: Supplementary figures.pdf
